NDA 19-941/S-014, S-015

AstraZeneca LP
1800 Concord Pike
P.O. Box 8355
Wilmington, DE 19803-8355

Attention: Patricia Palumbo, R.N., B.S.N., J.D.
Associate Director, Regulatory Affairs

Dear Ms. Palumbo:

Please refer to your supplemental new drug applications dated January 4, 2001, received January 5, 2001 (S-014) and October 4, 2002, received October 7, 2002 (S-015), submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for EMLA Cream and Anesthetic Disc.

Reference is also made to your submission dated March 22, 2002, for supplement S-014 which constituted a complete response to our November 26, 2001, action letter.

Supplemental S-014 provides for a revised package insert. The Clinical Studies subsection of the CLINICAL PHARMACOLOGY section, and WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, DOSAGE AND ADMINISTRATION, and HOW SUPPLIED sections of the labeling are revised. This supplement has been superseded by Supplement S-015; therefore, it is being retained in our files.

Supplemental S-015 provides for a change in the container-closure system of EMLA Cream 30 gm tube. The new container-closure system is a child-resistant container required by the Poison Prevention Packaging Act, 16CFR Part 1700.

We have completed our review of supplement S-015 and it is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical, and include the minor editorial revisions indicated below to the package insert and container and carton labels, submitted October 4, 2002. These revisions are terms of the approval of this application.

1. Add to the Container and Carton labels “For Topical Use Only.”

2. Retain the statement "This box does not include occlusive dressings."
3. Revise the statement from (b)(4)----------------------------- to “The greatest extent of analgesia, as measured by VAS scores, was attained after 5 to 15 minutes” in the Clinical Studies subsection of the CLINICAL PHARMACOLOGY section.

Please submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed to each application. Please mount individually ten of the copies on heavy-weight paper or similar material. Alternatively, you may submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDAs (January 1999). For administrative purposes, this/these submission(s) should be designated "FPL for approved supplement NDA 19-941/S-015.” Approval of this/these submission(s) by FDA is not required before the labeling is used.

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to the respective NDA and a copy to the following address:

   MEDWATCH, HF-2  
   FDA  
   5600 Fishers Lane  
   Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Kimberly Compton, Regulatory Project Manager, at (301) 827-7410.

Sincerely,

{See appended electronic signature page}

Bob Rappaport, M.D.  
Acting Director  
Division of Anesthetic, Critical Care, and Addiction Drug Products  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Celia Winchell
1/27/03 02:30:49 PM
for Bob A. Rappaport, Acting Division Director